Component
Absolute claudication walking distance
Absolute claudication walking distance. Species, exposure and limitations are retained in each linked claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Adding BH4 increased the reported walking-distance change to 28.15% only in the subgroup with baseline ADMA above 0.4 micromolar.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/citrulline-research/39985883.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0007fe7b3fcc746e77c450f3aca50ca2834c78b84aa83977b3078ae05051ab9c", "start_char": 0, "end_char": 1888, "text_sha256": "0007fe7b3fcc746e77c450f3aca50ca2834c78b84aa83977b3078ae05051ab9c"}
- experimental_model
- Phase II double-blind placebo-controlled crossover trial
- exposure
- 3 g citrulline twice daily for 12 weeks; additional BH4 0.45 g/day for two weeks in one arm
- limitations
- Preliminary trial; subgroup-dependent BH4 result and study-specific ADMA cutoff require confirmation; not a general supplement prescription.
- nutrient_topic
- Citrulline research collection; topical membership is not evidence of a direct dietary effect. · L-Citrulline
- organism
- Human, 51 peripheral-artery-disease patients
- plain_language
- The cofactor combination result depended on the measured starting state.
- primary_references
- [citrulline-p39985883] Nutritional L-Citrulline and Tetrahydrobiopterin in Peripheral Artery Disease: A Phase II Randomized Trial (CIPER Study). (2025). https://pubmed.ncbi.nlm.nih.gov/39985883/ DOI: 10.1016/j.jacadv.2025.101590
- tissue_or_cell_type
- Absolute claudication distance and plasma biomarkers
Citrulline: arginine recycling, nitrogen disposal and nutrient connections (2026-09-17) · lines 1217–1228
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Phase II double-blind placebo-controlled crossover trial · source_derived_draft · unverified_draft
### citrulline-pad-bh4-subgroup Adding BH4 increased the reported walking-distance change to 28.15% only in the subgroup with baseline ADMA above 0.4 micromolar. Condition category: normal nutrient_topic: Citrulline research collection; topical membership is not evidence of a direct dietary effect. plain_language: The cofactor combination result depended on the measured starting state. organism: Human, 51 peripheral-artery-disease patients tissue_or_cell_type: Absolute claudication distance and plasma biomarkers experimental_model: Phase II double-blind placebo-controlled crossover trial limitations: Preliminary trial; subgroup-dependent BH4 result and study-specific ADMA cutoff require confirmation; not a general supplement prescription. exposure: 3 g citrulline twice daily for 12 weeks; additional BH4 0.45 g/day for two weeks in one arm evidence_span: {"source_cache": "artifacts/citrulline-research/39985883.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0007fe7b3fcc746e77c450f3aca50ca2834c78b84aa83977b3078ae05051ab9c", "start_char": 0, "end_char": 1888, "text_sha256": "0007fe7b3fcc746e77c450f3aca50ca2834c78b84aa83977b3078ae05051ab9c"} [citrulline-p39985883] Nutritional L-Citrulline and Tetrahydrobiopterin in Peripheral Artery Disease: A Phase II Randomized Trial (CIPER Study). (2025). https://pubmed.ncbi.nlm.nih.gov/39985883/ DOI: 10.1016/j.jacadv.2025.101590
Complete structured claim and evidenceWalking-distance change was 20.11% with citrulline versus 5.73% with placebo, P=0.011.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/citrulline-research/39985883.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0007fe7b3fcc746e77c450f3aca50ca2834c78b84aa83977b3078ae05051ab9c", "start_char": 0, "end_char": 1888, "text_sha256": "0007fe7b3fcc746e77c450f3aca50ca2834c78b84aa83977b3078ae05051ab9c"}
- experimental_model
- Phase II double-blind placebo-controlled crossover trial
- exposure
- 3 g citrulline twice daily for 12 weeks; additional BH4 0.45 g/day for two weeks in one arm
- limitations
- Preliminary trial; subgroup-dependent BH4 result and study-specific ADMA cutoff require confirmation; not a general supplement prescription.
- nutrient_topic
- Citrulline research collection; topical membership is not evidence of a direct dietary effect. · L-Citrulline
- organism
- Human, 51 peripheral-artery-disease patients
- plain_language
- A patient-relevant walking endpoint improved in this preliminary PAD trial.
- primary_references
- [citrulline-p39985883] Nutritional L-Citrulline and Tetrahydrobiopterin in Peripheral Artery Disease: A Phase II Randomized Trial (CIPER Study). (2025). https://pubmed.ncbi.nlm.nih.gov/39985883/ DOI: 10.1016/j.jacadv.2025.101590
- tissue_or_cell_type
- Absolute claudication distance and plasma biomarkers
Citrulline: arginine recycling, nitrogen disposal and nutrient connections (2026-09-17) · lines 1204–1215
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Phase II double-blind placebo-controlled crossover trial · source_derived_draft · unverified_draft
### citrulline-pad-walking Walking-distance change was 20.11% with citrulline versus 5.73% with placebo, P=0.011. Condition category: normal nutrient_topic: Citrulline research collection; topical membership is not evidence of a direct dietary effect. plain_language: A patient-relevant walking endpoint improved in this preliminary PAD trial. organism: Human, 51 peripheral-artery-disease patients tissue_or_cell_type: Absolute claudication distance and plasma biomarkers experimental_model: Phase II double-blind placebo-controlled crossover trial limitations: Preliminary trial; subgroup-dependent BH4 result and study-specific ADMA cutoff require confirmation; not a general supplement prescription. exposure: 3 g citrulline twice daily for 12 weeks; additional BH4 0.45 g/day for two weeks in one arm evidence_span: {"source_cache": "artifacts/citrulline-research/39985883.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0007fe7b3fcc746e77c450f3aca50ca2834c78b84aa83977b3078ae05051ab9c", "start_char": 0, "end_char": 1888, "text_sha256": "0007fe7b3fcc746e77c450f3aca50ca2834c78b84aa83977b3078ae05051ab9c"} [citrulline-p39985883] Nutritional L-Citrulline and Tetrahydrobiopterin in Peripheral Artery Disease: A Phase II Randomized Trial (CIPER Study). (2025). https://pubmed.ncbi.nlm.nih.gov/39985883/ DOI: 10.1016/j.jacadv.2025.101590
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.